Mainstream

Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase

Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase

Post ContentroivRead More

You might also be interested in reading Bitcoin nears $65,000 as cooling U.S. inflation guts the Fed rate-hike trade.

August 11, 2025
In Mainstream